AU2002219555A1 - VLA-4 Inhibitors - Google Patents
VLA-4 InhibitorsInfo
- Publication number
- AU2002219555A1 AU2002219555A1 AU2002219555A AU2002219555A AU2002219555A1 AU 2002219555 A1 AU2002219555 A1 AU 2002219555A1 AU 2002219555 A AU2002219555 A AU 2002219555A AU 2002219555 A AU2002219555 A AU 2002219555A AU 2002219555 A1 AU2002219555 A1 AU 2002219555A1
- Authority
- AU
- Australia
- Prior art keywords
- vla
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010008212 Integrin alpha4beta1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000402890 | 2000-12-28 | ||
JP2000402890 | 2000-12-28 | ||
JP2001149923 | 2001-05-18 | ||
JP2001149923 | 2001-05-18 | ||
PCT/JP2001/011641 WO2002053534A1 (en) | 2000-12-28 | 2001-12-28 | Vla-4 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002219555A1 true AU2002219555A1 (en) | 2003-01-23 |
AU2002219555B2 AU2002219555B2 (en) | 2006-11-30 |
Family
ID=26607210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002219555A Ceased AU2002219555B2 (en) | 2000-12-28 | 2001-12-28 | VLA-4 Inhibitors |
Country Status (17)
Country | Link |
---|---|
US (1) | US7157487B2 (en) |
EP (1) | EP1346982B1 (en) |
JP (1) | JP4212358B2 (en) |
KR (1) | KR100884877B1 (en) |
CN (1) | CN100471838C (en) |
AR (1) | AR035218A1 (en) |
AT (1) | ATE524441T1 (en) |
AU (1) | AU2002219555B2 (en) |
BR (1) | BR0116608A (en) |
CA (1) | CA2430978C (en) |
HK (2) | HK1060726A1 (en) |
IL (1) | IL156064A0 (en) |
MX (1) | MXPA03005838A (en) |
NO (1) | NO326014B1 (en) |
RU (1) | RU2290403C2 (en) |
TW (1) | TWI312779B (en) |
WO (1) | WO2002053534A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0031315D0 (en) * | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
PL375149A1 (en) * | 2002-10-03 | 2005-11-28 | F.Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
WO2004099136A1 (en) * | 2003-05-09 | 2004-11-18 | Daiichi Pharmaceutical Co., Ltd. | Process for producing pyrrolidine derivative |
EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
TWI340134B (en) * | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
US20070149606A1 (en) * | 2003-12-26 | 2007-06-28 | Daiichi Pharmaceutical Co.,Ltd. | Process for producing phenylacetic acid derivative |
EP1698621A4 (en) * | 2003-12-26 | 2008-11-19 | Daiichi Seiyaku Co | Method for producing pyrrolidine derivative |
CN1938293A (en) | 2004-03-24 | 2007-03-28 | 捷瑞尼股份公司 | New compounds for the inhibition of angiogenesis and use of thereof |
JP2005350417A (en) * | 2004-06-11 | 2005-12-22 | Dai Ichi Seiyaku Co Ltd | Method for producing pyrrolidine derivative using reductive etherification method |
TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008506702A (en) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | Method for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN101022802A (en) | 2004-07-22 | 2007-08-22 | Ptc医疗公司 | Thienopyridines for treating hepatitis c |
JP2006056830A (en) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | 2-arylaminobenzoxazole derivative |
JP2008520744A (en) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
EP1939189A4 (en) * | 2005-08-26 | 2013-03-13 | Shionogi & Co | Derivative having ppar agonistic activity |
JP5107724B2 (en) * | 2005-12-13 | 2012-12-26 | 第一三共株式会社 | VLA-4 inhibitor |
EP2004654B1 (en) | 2006-04-04 | 2013-05-22 | The Regents of the University of California | Pyrazolopyrimidine derivatives for use as kinase antagonists |
DE102006021878A1 (en) * | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazole substituted carboxylic acids, process for their preparation and their use as medicaments |
US7858645B2 (en) * | 2006-11-01 | 2010-12-28 | Hoffmann-La Roche Inc. | Indazole derivatives |
US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101653842B1 (en) * | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | Certain chemical entities, compositions and methods |
US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
PT2376485T (en) | 2008-12-19 | 2018-03-12 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
JP5785940B2 (en) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス, エルエルシー | Triazine derivatives and their therapeutic applications |
EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
JP2012529530A (en) | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Isoquinoline, quinoline and quinazoline derivatives as inhibitors of hedgehog signaling |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
ES2601226T3 (en) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
CA2824197C (en) | 2011-01-10 | 2020-02-25 | Michael Martin | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
EP2678018A4 (en) | 2011-02-23 | 2015-09-30 | Intellikine Llc | Combination of kanase inhibitors and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (en) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS |
AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
SG11201502331RA (en) | 2012-09-26 | 2015-04-29 | Univ California | Modulation of ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
BR112016007467B1 (en) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN113620958A (en) | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
BR112017009513A2 (en) * | 2014-11-06 | 2018-02-06 | Basf Se | use of a heterobicyclic compound, use of compounds i, compounds, agricultural or veterinary composition, method for pest control or control, method for crop and seed protection |
CA2988502A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Nuclear receptor modulators |
CA2998469A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969687A (en) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
JP7214882B2 (en) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
KR20220047323A (en) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Compounds for Inhibiting Alpha 4 Beta 7 Integrin |
AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
DE2500157C2 (en) * | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-acyl-4- (2-aminoethyl) benzoic acids, their salts and esters, process for their preparation and their use |
DE2706977A1 (en) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | BENZOESAEURS AND THEIR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
US4184658A (en) * | 1978-02-13 | 1980-01-22 | General Electric Company | Cushion mount for prime mover |
EP0023569B1 (en) * | 1979-07-13 | 1983-06-22 | Dr. Karl Thomae GmbH | Derivatives of carboxylic acids, their preparation and medicaments containing them |
JPS60181081A (en) * | 1984-02-29 | 1985-09-14 | Kaken Pharmaceut Co Ltd | Novel bisbenzofuranyl ketone derivative and its preparation |
JPH04112868A (en) * | 1990-09-03 | 1992-04-14 | Otsuka Pharmaceut Co Ltd | Phenylcarboxylic acid derivative having substituted hetero ring |
JPH0543574A (en) * | 1991-08-13 | 1993-02-23 | Wakamoto Pharmaceut Co Ltd | Hetero ring-substituted tetrazole-1-acetic acid derivative |
FR2694295B1 (en) * | 1992-07-28 | 1994-09-02 | Adir | New peptides derived from trifluoromethyl ketones, their preparation process and the pharmaceutical compositions containing them. |
US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
ES2103181B1 (en) | 1994-08-01 | 1998-04-01 | Menarini Lab | NAFTALENIC AMIDES WITH ANTAGONIST ACTION OF THE LEUKOTRENEES. |
GB9408936D0 (en) * | 1994-05-05 | 1994-06-22 | Cancer Res Inst | Anti-cancer compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
WO1997002024A1 (en) * | 1995-06-30 | 1997-01-23 | Smithkline Beecham Corporation | Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
AU3738597A (en) | 1996-07-25 | 1998-02-20 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
JP2000516958A (en) | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | Phospholipase enzyme inhibitors |
DE19647381A1 (en) | 1996-11-15 | 1998-05-20 | Hoechst Ag | New heterocycles as leukocyte adhesion inhibitors and VLA-4 antagonists |
US6117901A (en) * | 1996-11-22 | 2000-09-12 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use |
AU739035B2 (en) * | 1996-11-22 | 2001-10-04 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
SK9372000A3 (en) | 1997-12-23 | 2002-03-05 | Rhone Poulenc Rorer Ltd | Substituted beta-alanines |
EE200000522A (en) | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity |
SI1082302T1 (en) | 1998-05-28 | 2004-06-30 | Biogen, Inc. | A vla-4 inhibitor: omepupa-v |
WO1999064392A1 (en) * | 1998-06-08 | 1999-12-16 | Ajinomoto Co., Inc. | Benzamidine derivative |
PL345308A1 (en) | 1998-06-30 | 2001-12-03 | Pfizer Prod Inc | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
JP2002521375A (en) * | 1998-07-23 | 2002-07-16 | アストラゼネカ アクチエボラーク | Compound |
GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
CN1323295A (en) | 1998-08-26 | 2001-11-21 | 阿文蒂斯药物有限公司 | AZA-bicycles which modulate the inhibition of cell adhesion |
GB9821199D0 (en) * | 1998-09-30 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
WO2000049005A1 (en) | 1999-02-16 | 2000-08-24 | Aventis Pharma Limited | Bicyclic compounds and their use as integrin receptor ligands |
JP2000344666A (en) * | 1999-04-01 | 2000-12-12 | Sankyo Co Ltd | Ameliorating agent for glycometabolism and lipid metabolism |
WO2000061580A1 (en) | 1999-04-12 | 2000-10-19 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compounds as integrin antagonists |
EP1189883B1 (en) | 1999-05-05 | 2004-11-03 | Aventis Pharma Limited | Substituted pyrrolidines as cell adhesion inhibitors |
EP1176959B1 (en) * | 1999-05-05 | 2006-03-08 | Merck & Co., Inc. | Novel prolines as antimicrobial agents |
CA2370805C (en) | 1999-05-05 | 2012-07-03 | Aventis Pharma Limited | Ureas as cell adhesion modulators |
DE60041487D1 (en) | 1999-05-05 | 2009-03-19 | Aventis Pharma Ltd | SUBSTITUTED BICYCLIC COMPOUNDS |
IL146288A0 (en) | 1999-06-30 | 2002-07-25 | Daiichi Seiyaku Co | Vla-4 inhibitor compounds |
US6756378B2 (en) * | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
CA2380817A1 (en) | 1999-08-13 | 2001-02-22 | Biogen, Inc. | Cell adhesion inhibitors |
ATE374180T1 (en) * | 1999-11-10 | 2007-10-15 | Sanofi Aventis Deutschland | N-ACYLPYRROLIDINE-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA |
AP2002002565A0 (en) * | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
GB0001346D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
DE10006453A1 (en) | 2000-02-14 | 2001-08-16 | Bayer Ag | New piperidylcarboxylic acid derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological diseases, e.g. atherosclerosis, asthma, diabetes, rheumatoid arthritis or transplant rejection |
GB0004686D0 (en) | 2000-02-28 | 2000-04-19 | Aventis Pharma Ltd | Chemical compounds |
AU2001235806A1 (en) | 2000-03-01 | 2001-09-12 | Aventis Pharma Limited | 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
KR100568841B1 (en) * | 2000-07-19 | 2006-04-10 | 에프. 호프만-라 로슈 아게 | Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
-
2001
- 2001-12-28 CN CNB018214843A patent/CN100471838C/en not_active Expired - Fee Related
- 2001-12-28 IL IL15606401A patent/IL156064A0/en unknown
- 2001-12-28 WO PCT/JP2001/011641 patent/WO2002053534A1/en active Application Filing
- 2001-12-28 RU RU2003123115/04A patent/RU2290403C2/en active
- 2001-12-28 MX MXPA03005838A patent/MXPA03005838A/en active IP Right Grant
- 2001-12-28 AU AU2002219555A patent/AU2002219555B2/en not_active Ceased
- 2001-12-28 KR KR1020037008702A patent/KR100884877B1/en not_active IP Right Cessation
- 2001-12-28 CA CA2430978A patent/CA2430978C/en not_active Expired - Fee Related
- 2001-12-28 AT AT01272548T patent/ATE524441T1/en not_active IP Right Cessation
- 2001-12-28 BR BR0116608-5A patent/BR0116608A/en not_active IP Right Cessation
- 2001-12-28 TW TW090133464A patent/TWI312779B/zh not_active IP Right Cessation
- 2001-12-28 AR ARP010106105A patent/AR035218A1/en unknown
- 2001-12-28 JP JP2002554653A patent/JP4212358B2/en not_active Expired - Fee Related
- 2001-12-28 EP EP01272548A patent/EP1346982B1/en not_active Expired - Lifetime
- 2001-12-28 US US10/451,159 patent/US7157487B2/en not_active Expired - Fee Related
-
2003
- 2003-06-27 NO NO20032994A patent/NO326014B1/en not_active IP Right Cessation
-
2004
- 2004-05-07 HK HK04103218.6A patent/HK1060726A1/en not_active IP Right Cessation
-
2006
- 2006-02-08 HK HK06101636.2A patent/HK1081545A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002219555A1 (en) | VLA-4 Inhibitors | |
HK1081545A1 (en) | Vla-4 inhibitors | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
AU2001244399A1 (en) | Gamma-secretase inhibitors | |
AU2002250394A1 (en) | Rho-kinase inhibitors | |
AU2002245709A1 (en) | Rho-kinase inhibitors | |
AU2001237041A1 (en) | Kinase inhibitors | |
AU2001293373A1 (en) | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | |
AU2002220241A1 (en) | Parb inhibitors | |
AU2001234088A1 (en) | TNF-alpha inhibitors | |
AU2001265089A1 (en) | Rc-timer scheme | |
AU2001285750A1 (en) | Urokinase inhibitors | |
AU6381701A (en) | Bisamidino compounds as nhe-3 inhibitors | |
AU5248800A (en) | Fading inhibitors | |
AU2001247589A1 (en) | Non-amidine containing protease inhibitors | |
AU2001236052A1 (en) | Urease inhibitors | |
AU2002211662A1 (en) | Nf-kappab inhibitors | |
AU2002222627A1 (en) | Tak1 inhibitors | |
AU2001259218A1 (en) | Substituted phenyl farnesyltransferase inhibitors | |
AU2001255090A1 (en) | Cdk inhibitors having 3-hydroxychromen-4-one structure | |
AU2001244562A1 (en) | Neovascularization inhibitors | |
AU3235100A (en) | Prothease inhibitors | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
AU1588901A (en) | Protease inhibitors |